Business
Aptevo Announces Positive Duration of Remission Data from Phase 1b Expansion Trial Evaluating the Bispecific APVO436 for AML
Phase 2 Trials in Relapsed/Refractory and Frontline Settings Planned, APVO436 to be administered in Combination with Emerging Standard of CareNew Data Adds to
About this update from Aptevo Therapeutics Inc.
[{"type":"text","content":"Phase 2 Trials in Relapsed/Refractory and Frontline Settings Planned, APVO436 to be administered in Combination with Emerging Standard of CareNew Data Adds to Growing Body of Clinical Evidence in Support of APVO436 Clinical PotentialSEATTLE, WA / ACCESSWIRE / July 18, 2023 / Aptevo Therapeutics Inc. (\"Aptevo\" or the \"Company\") (Nasdaq;APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced that its bispecific AML drug candidate APVO436, in combination with emerging standard of care venetoclax and azacitidine, achieved positive duration of remission results in its Phase 1b dose escalation trial. The Company is also providing an update of its APVO436 Phase 2 program design that will include both frontline and relapsed/refractory trials beginning later in the second half of 2023.Duration of Remission (DOR)Positive and clinically meaningful DOR results was observed from the company's bispecific AML drug candidate APVO436 in combination with the emerging standard of care (venetoclax + azacitidine) in venetoclax treatment naïve patients, as follows:High response rate observed - 82% (9/11) of patients had a favorable response and were eligible for inclusion in the DOR analysisMultiple patients moved to transplant - 3/11 patients responded sufficiently to move to stem cell transplant - receiving stem cell transplant is the treatment option with the best probability for survival and highest benefit to patientsSustained complete response - Of the patients with responses, one patient remained on study with sustained complete response for 8 cycles (the maximum allowed per protocol) which translated into at least 8 months of response durationMedian DOR not reached - The median DOR was not reached, which is clinically meaningful because a substantial number of patients either stayed on treatment or moved to transplant and did not experience a relapse eventThis DOR data adds to a growing body of clinical evidence (safety, tolerability, efficacy and now durability), that provides strong support for the further development of APVO436 in combination therapy for patients with AML.Phase 2 Program UpdateThe Company's APVO436 Phase 2 program will further evaluate the triplet combination of APVO436 + venetoclax ...